AstraZeneca Pays $630M for Complete Global Rights Over AbelZeta’s CAR T
The arrangement will boost AstraZeneca’s cell therapy portfolio as the pharma targets $80 billion in revenue by 2030.
AstraZeneca Pays $630M for Complete Global Rights Over AbelZeta’s CAR T Read More »
